Aileron Therapeutics Inc (ALRN)

2.7700 -0.0100 (-0.36%)
Closed USD Disclaimer
2.8000 +0.0300 (+1.0830%)

Aileron Therapeutics Inc Company Profile

Equity Type
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.
Contact Information
Boston,02210 United States
617 995 0900
617 995 2410
Top Executives
Jeffrey Allen Bailey 59 2018 Independent Chairman of the Board
Brian J. Druker 66 2018 Member of Scientific Advisory Board
William T. McKee 60 2019 Independent Director
Carol L. Prives 0 2018 Member of Scientific Advisory Board
Alan F. List 67 2018 Member of Scientific Advisory Board
Ulrich Steidl 0 0000 Member of Scientific Advisory Board
Jodie Pope Morrison 47 2017 Independent Director
Manuel C. Aivado 52 2014 President, CEO & Director
Reinhard J. Ambros 67 2013 Independent Lead Director
Josef H. von Rickenbach 67 2019 Independent Director
Nolan H. Sigal 72 2019 Independent Director
Clear All
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.